InterMune Inc. (ITMN)
ITMN (NASDAQ:Drugs)
$9.58

-0.38
-3.82%
Today's Range: 9.53 - 9.87 |
ITMN Avg Daily Volume: 1,295,300
| Last Update: 05/24/13 - 4:00 PM EDT |
| Volume: 826,352 |
| YTD Performance: -0.93%
|
| Open: $9.87 |
| Previous Close: $9.96 |
| 52 Week Range: $7.21 -
$12.77 |
| Oustanding Shares: 81,684,233 |
| Market Cap: 783,543,974 |
6-Month Chart
TheStreet Ratings Grade for ITMN
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
11 |
11 |
11 |
11 |
| Moderate Buy |
0 |
0 |
0 |
0 |
| Hold |
1 |
1 |
2 |
2 |
| Moderate Sell |
1 |
1 |
1 |
1 |
| Strong Sell |
0 |
0 |
0 |
0 |
| Mean Rec. |
1.38 |
1.38 |
1.50 |
1.50 |
| Latest Dividend: |
0.00 |
| Latest Dividend Yield: |
0.00% |
| Dividend Ex-Date: |
12/31/69 |
| Price Earnings Ratio: |
-3.49 |
|
| Price Earnings Comparisons: |
| ITMN |
Sector Avg. |
S&P 500 |
| -3.49 |
0.00 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
8.35%
|
-2.73%
|
7.50%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
2.10 |
-0.46 |
-0.19 |
| Net Income |
0.00 |
0.59 |
0.00 |
| EPS |
0.00 |
-0.12 |
0.00 |
| Earnings for ITMN: |
| EBITDA |
-0.19B |
| Revenue |
0.03B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$-0.69 |
$-0.70 |
$-2.75 |
$-1.94 |
| Number of Analysts |
10 |
10 |
11 |
11 |
| High Estimate |
$-0.60 |
$-0.62 |
$-2.52 |
$-1.70 |
| Low Estimate |
$-0.76 |
$-0.74 |
$-2.95 |
$-2.34 |
| Prior Year |
$-0.78 |
$-0.70 |
$-2.82 |
$-2.75 |
| Growth Rate (Year over Year) |
11.41% |
0.00% |
2.51% |
29.50% |
Jan 16, 2013 | 8:38 AM EST
ITMN was upgraded to Buy from Neutral, UBS said. $15 price target. Short term hurdles removed.
Aug 15, 2012 | 8:13 AM EDT
Shares of ITMN now seen reaching $8.50, UBS said. Estimates also lowered to reflect Esbriet pricing and sales. Neutral rating.